Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a lipoprotein-associated enzyme that cleaves oxidized phosphatidylcholines, generating pro-atherosclerotic lysophosphatidylcholine and oxidized free fatty acids. Lp-PLA2 is independently associated with cardiovascular disease (CVD) in a variety of populations. Coronary calcium is a measure of subclinical CVD, and progression of coronary calcification predicts future CVD events. In type 1 diabetes there is an increase in coronary calcium and CVD despite a favorable lipid profile. Levels of Lp-PLA2 in type 1 diabetes are not known, nor is the relationship between Lp-PLA2 and progression of coronary calcification.
Methods:
The Coronary Artery Calcification in Type 1 Diabetes study measured coronary calcium by electron-beam computed tomography twice over a 2.6 ± 0.3-year interval. Lp-PLA2 mass and activity were measured at baseline (n = 1,097 subjects, 506 with and 591 without type 1 diabetes).
Results:
In type 1 diabetes Lp-PLA2 mass was marginally higher (285 ± 79 vs. 278 ± 78 ng/mL, P = 0.1), and Lp-PLA2 activity was significantly lower (137 ± 30 vs. 146 ± 36 nmol/min/mL, P < 0.0001) than in those without diabetes. There was a greater proportion of those with progression of coronary calcification in type 1 diabetes compared with those without diabetes (24% vs. 10%, P < 0.0001). Lp-PLA2 activity was independently associated with progression of coronary calcification in multivariate analysis (4th quartile verses bottom three quartiles, odds ratio = 1.77 [1.08–2.91], P = 0.02). LpPLA2 mass was not significantly associated with progression of coronary calcification in this cohort (P = 0.09).
Conclusions:
Lp-PLA2 activity predicts progression of subclinical atherosclerosis in individuals with and without type 1 diabetes.
Get full access to this article
View all access options for this article.
References
1.
KrolewskiAS, KosinskiEJ, WarramJH, LelandOS, BusickEJ, AsmalAC, RandLI, ChristliebAR, BradleyRF, KahnCR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol, 1987; 59:750–755.
2.
BergholdtR, HedingP, NielsenK, NolsøeR, SparreT, StørlingJ, NerupJ, PociotF, Mandrup-PoulsenT. Type 1 database mellitus: an inflammatory disease of the islet. Adv Exp Med Biol, 2004; 552:129–153.
3.
SchramMT, ChaturvediN, SchalkwijkCG, FullerJH, StehouwerCD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia, 2005; 48:370–378.
4.
O'RourkeRA, BrundageBH, FroelicherVF, GreenlandP, GrundySM, HachamovitchR, PohostGM, ShawLJ, WeintraubWS, WintersWLJr, ForresterJS, DouglasPS, FaxonDP, FisherJD, GregoratosG, HochmanJS, HutterAMJr, KaulS, WolkMJ. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation, 2000; 102:126–140.
5.
AradY, SpadaroLA, GoodmanK, NewsteinD, GuerciAD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol, 2000; 36:1253–1260.
6.
WongND, HsuJC, DetranoRC, DiamondG, EisenbergH, GardinJM. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol, 2000; 86:495–498.
7.
RaggiP, CallisterTQ, CooilB, HeZX, LippolisNJ, RussoDJ, ZelingerA, MahmarianJJ. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation, 2000; 101:850–855.
8.
ColhounHM, RubensMB, UnderwoodSR, FullerJH. The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J Am Coll Cardiol, 2000; 36:2160–2167.
9.
DabeleaD, KinneyG, Snell-BergeonJK, HokansonJE, EckelRH, EhrlichJ, GargS, HammanRF, RewersM. Coronary Artery Calcification in Type 1 Diabetes Study. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes, 2003; 52:2833–2839Erratum in Diabetes 2004;53:2177.
10.
SchurginS, RichS, MazzoneT. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care, 2001; 24:335–338.
11.
ColhounHM, SchalkwijkC, RubensMB, StehouwerCD. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care, 2002; 25:1813–1817.
12.
ForrestKY, BeckerDJ, KullerLH, WolfsonSK, OrchardTJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis, 2000; 148:159–169.
13.
RaggiP, CallisterTQ, ShawLJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol, 2004; 24:1272–1277.
14.
RaggiP, CooilB, ShawLJ, AboulhsonJ, TakasuJ, BudoffM, CallisterTQ. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol, 2003; 92:827–829.
15.
BudoffMJ, RaggiP. Coronary artery disease progression assessed by electron-beam computed tomography. Am J Cardiol, 2001; 88:46E–50E.
16.
MacpheeCH, NelsonJ, ZalewskiA. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol, 2006; 6:154–161.
17.
ZalewskiA, MacpheeC. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol, 2005; 25:923–931.
18.
StafforiniDM, TjoelkerLW, McCormickSP, VaitkusD, McIntyreTM, GrayPW, YoungSG, PrescottSM. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem, 1999; 274:7018–7024.
19.
GarzaCA, MontoriVM, McConnellJP, SomersVK, KulloIJ, Lopez-JimenezF. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc, 2007; 82:159–165.
20.
IribarrenC, GrossMD, DarbinianJA, JacobsDRJr, SidneyS, LoriaCM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol, 2005; 25:216–221.
CaslakeMJ, PackardCJ, SucklingKE, HolmesSD, ChamberlainP, MacpheeCH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis, 2000; 150:413–419.
23.
GaziI, LouridaES, FilippatosT, TsimihodimosV, ElisafM, TselepisAD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem, 2005; 51:2264–2273.
24.
Snell-BergeonJK, HokansonJE, JensenL, MacKenzieT, KinneyG, DabeleaD, EckelRH, EhrlichJ, GargS, RewersM. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care, 2003; 26:2923–2928.
25.
AgatstonAS, JanowitzWR, HildnerFJ, ZusmerNR, ViamonteMJr, DetranoR. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol, 1990; 15:827–832.
26.
HokansonJE, MacKenzieT, KinneyG, Snell-BergeonJK, DabeleaD, EhrlichJ, EckelRH, RewersM. Evaluating changes in coronary artery calcium: an analytic method that accounts for interscan variability. AJR Am J Roentgenol, 2004; 182:1327–1332.
27.
Lp-PLA2 Studies Collaboration. ThompsonA, GaoP, OrfeiL, WatsonS, Di AngelantonioE, KaptogeS, BallantyneC, CannonCP, CriquiM, CushmanM, HofmanA, PackardC, ThompsonSG, CollinsR, DaneshJ. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 2010; 375:1536–1544.
28.
KoenigW, KhuseyinovaN, LowelH, TrischlerG, MeisingerC. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation, 2004; 110:1903–1908.
29.
CarpenterKL, DennisIF, ChallisIR, OsbornDP, MacpheeCH, LeakeDS, ArendsMJ, MitchinsonMJ. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett, 2001; 505:357–363.
30.
ShiY, ZhangP, ZhangL, OsmanH, MohlerER3rd, MacpheeC, ZalewskiA, PostleA, WilenskyRL. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis, 2007; 191:54–62.
31.
ReillyMP, WolfeML, LocalioAR, RaderDJ. Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. Atherosclerosis, 2004; 173:69–78.
